Skip to main content

What Biogen's 8-K filings say: 9 filings, latest Oct 28, 2026

Biogen filed its latest 8-K with the SEC on Oct 28, 2026. It discusses acquisition completed and margin pressure.

Public (BIIB)Biotechnology Research10,000+ employeesbiogen.comLinkedIn

Get Biogen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Biogen this week? Use Autobound signals for biogen.com.
Filed
Oct 28, 2026
Filings
9
Signals
27

Source: Autobound Signal API · 76 signals tracked for Biogen · updated

8-K · latest 10

What Biogen's 8-K filings say

  1. 8-K

    Filed · 2 signals

    SEC EDGAR
    • Acquisition completedNeutral

      Biogen Closes Acquisition of RayThera Inc. Recording $284M in Upfront and IPR&D Expenses

      Biogen incurred $284 million of acquired IPR&D, upfront and milestone expense in Q3 2026 primarily related to the stock acquisition of RayThera Inc.

      $284M

      acquired IPR&D, upfront and milestone expense primarily related to RayThera Inc. acquisition

    • Margin pressureNegative

      Biogen reports Q3 GAAP diluted EPS decline to $(0.14) amid higher expenses

      Third quarter 2026 GAAP diluted EPS fell 104% to $(0.14), while Non-GAAP diluted EPS declined 46% to $2.62, driven by $284 million in acquired IPR&D, upfront and milestone expenses, as well as higher R&D and SG&A costs.

      $284M

      acquired IPR&D, upfront and milestone expense primarily related to the acquisition of RayThera Inc.

      -104%

      decline in GAAP diluted EPS compared to Q3 2025

  2. 8-K

    Filed · 3 signals

    SEC EDGAR
    • Acquisition announcedPositive

      Biogen to spend up to $484M on R&D acquisitions and licensing deals in Q2 & Q3 2026

      Biogen is allocating significant capital for external innovation, with up to $484 million earmarked for acquiring R&D assets and funding collaboration agreements.

      $484M

      Maximum expected expense for acquired in-process research and development, upfront payments, and milestones across Q2 and Q3 2026 ($164M in Q2 + up to $320M...

    • Margin pressureNegative

      Biogen flags up to $484M in R&D charges, pressuring Q2 & Q3 earnings.

      Biogen is absorbing a $164M charge in Q2 and forecasts another $290M-$320M in Q3 for R&D deals, significantly impacting profitability.

      $484M

      Total expected R&D-related charges against earnings for Q2 and Q3 2026 (using $164M for Q2 and high-end $320M for Q3).

    • Capex increasePositive

      Biogen investing over $450M in external R&D acquisitions and partnerships.

      Biogen is executing a major capital allocation strategy, spending $164M in Q2 and up to $320M more in Q3 to acquire R&D assets and fund collaborations.

      $484M

      Total investment in external R&D, including acquisitions and collaborations, across Q2 and Q3 2026 (using $164M for Q2 and high-end $320M for Q3).

  3. 8-K

    Filed · 2 signals

    SEC EDGAR
  4. 8-K

    Filed · 5 signals

    SEC EDGAR

Earlier 8-K filings

Showing 10 of 27 filing signals. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Biogen with the Signal API

One POST /v1/companies/enrich call with biogen.com returns Biogen 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","signal_types":["sec-8k"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.

Talk to sales

Same industry

Questions about Biogen 8-K

When did Biogen file its latest 8-K?
Biogen filed its latest 8-K on Oct 28, 2026. The one before it was filed on Jul 1, 2026.
What did Biogen disclose in its latest 8-K?
From the filing dated Oct 28, 2026: Biogen Closes Acquisition of RayThera Inc. Recording $284M in Upfront and IPR&D Expenses
Where can I read Biogen's 8-K filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/biib-20261028.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →